Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Halozyme is a clinical-stage biotechnology company focused on two pillars: Our ENHANZE™ drug delivery technology and developing and commercializing novel cancer therapies that target the tumor microenvironment. We are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, Roche, Pfizer, Janssen, Shire, AbbVie, Lilly, BMS, and Alexion for our ENHANZE drug delivery technology, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. This technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. Our lead proprietary oncology program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. By breaking down potential barriers to cancer, PEGPH20 may help make existing treatments more effective by allowing therapies to reach the tumor.
Set up a meeting